Argos Therapeutics, a developer of immunotherapy programs, has licensed a protein that could be used to treat autoimmune disorders and to possibly combat transplant rejections.
Beckman Coulter, which is based in California, licensed therapeutic use rights for the protein known as CD83 to Argos. It retained rights to develop diagnostic uses for CD83.
Patented therapeutic use of CD83 was filed by the Dana-Farber Cancer Institute before Beckman Coulter acquired the rights. CD83 is currently being tested.
Autoimmune disorders are caused when a patient’s immune system attacks its own cells. Transplant rejection takes place with a patient’s immune system attacks the transplanted organ or tissue.
Argos recently changed its name from Merix Bioscience.
Argos Therapeutics: www.argoestherapeutics.com